BioTime (BTX)’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM
1/31/2013 10:00:08 AM
More...
|
BioTime (BTX) and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers
8/16/2012 9:37:37 AM
More...
|
BioTime (BTX)'s Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products
4/24/2012 8:42:13 AM
More...
|
BioTime (BTX)’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM
3/22/2012 6:51:09 AM
More...
|
ReCyte Therapeutics and OncoCyte Corporation Release: BioTime (BTX) Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute
1/24/2012 6:55:12 AM
More...
|
BioTime (BTIM.PK)'s Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
8/24/2011 7:06:35 AM
More...
|
BioTime (BTIM.PK) Subsidiary OncoCyte Corporation Receives Second $2,000,000 Equity Tranche; BioTime Plans Additional $2,250,000 Investment
1/7/2010 8:57:35 AM
More...
|
New BioTime (BTIM.PK) Subsidiary, OncoCyte Corporation, Receives $2 Million Equity Financing to Develop Cancer Treatments Using Stem Cell Technology
10/16/2009 8:30:11 AM
More...
|